Intelligence · Clinical Development
Pipeline search results
Programs matching “breast-cancer” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 272 pipeline programs matching "breast-cancer" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
INT230-6
INTENSITY THERAPEUTICS, INC.
Breast Cancer
2 trials -
Indibulin
Alaunos Therapeutics
Metastatic Breast Cancer
1 trial -
Inetetamab
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
Iniparib
Sanofi Pasteur
Breast Cancer, Metastatic
1 trial -
Ixabepilone Injection
Allarity Therapeutics
Metastatic Breast Cancer
1 trial -
Ixazomib
Takeda
Triple-Negative Breast Cancer
1 trial -
LBL-024 for Injection
The First People's Hospital of Lianyungang
Triple Negative Breast Cancer
1 trial -
Lapatinib
United Therapeutics Europe Ltd
Breast Cancer
1 trial -
Letrozole
United Therapeutics Europe Ltd
Breast Cancer
1 trial -
Liposomal doxorubicin hydrochloride
Teva Pharma GmbH
Breast Cancer
1 trial -
Low dose FRα vaccine
Marker Therapeutics
Breast Cancer
1 trial -
MKC-1
CASI Pharmaceuticals
Breast Cancer
1 trial -
Myocet (Non-pegylated liposomal doxorubicin (NPLD))
Sana Biotechnology
Breast Cancer
1 trial -
NERATINIB
PUMA BIOTECHNOLOGY, INC.
Stage IV (Metastatic) Breast Cancer
1 trial -
NJMU-BC01
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
Neoadjuvant Chemotherapy (NACT)
The First People's Hospital of Lianyungang
HR+/HER2- Breast Cancer
1 trial -
Neoadjuvant Chemotherapy combined with Neoadjuvant Radiotherapy
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
Neoadjuvant therapy: TCbHPy
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Metastatic Breast Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
HER2-positive Breast Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
HER2 Amplified Breast Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Early Stage HER2+ Breast Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Anatomic Stage I Breast Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Early-stage Breast Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.